Cargando…
Development of Group B Coxsackievirus as an Oncolytic Virus: Opportunities and Challenges
Oncolytic viruses have emerged as a promising strategy for cancer therapy due to their dual ability to selectively infect and lyse tumor cells and to induce systemic anti-tumor immunity. Among various candidate viruses, coxsackievirus group B (CVBs) have attracted increasing attention in recent year...
Autores principales: | Liu, Huitao, Luo, Honglin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227215/ https://www.ncbi.nlm.nih.gov/pubmed/34198859 http://dx.doi.org/10.3390/v13061082 |
Ejemplares similares
-
Enhanced genomic stability of new miRNA-regulated oncolytic coxsackievirus B3
por: Liu, Huitao, et al.
Publicado: (2022) -
Coxsackievirus Type B3 Is a Potent Oncolytic Virus against KRAS-Mutant Lung Adenocarcinoma
por: Deng, Haoyu, et al.
Publicado: (2019) -
Coxsackievirus B3—Its Potential as an Oncolytic Virus
por: Geisler, Anja, et al.
Publicado: (2021) -
MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer
por: Liu, Huitao, et al.
Publicado: (2021) -
MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer
por: Liu, Huitao, et al.
Publicado: (2020)